Volume 5.04 | Feb 7

Prostate Cell News 5.04 February 7, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Researchers Advance Findings on Key Gene Related to Cancer Metastasis
New evidence reported by researchers lends support to the hypothesis that the SSeCKS/AKAP12 gene is a key inhibitor of prostate cancer metastasis. [Press release from Roswell Park Cancer Institute discussing online prepublication in Cancer Research] Press Release | Abstract
Use TeSR-E7 to generate iPS cells with high quality colony morphology for easy identification and rapid subcloning. Request your sample.
PUBLICATIONS (Ranked by impact factor of the journal)

A Novel Direct Activator of AMPK Inhibits Prostate Cancer Growth by Blocking Lipogenesis
Investigators showed that direct activation of 5’AMP-activated kinase (AMPK) inhibits prostate cancer (PCa) cell growth in androgen sensitive and castration resistant PCa models, induces mitotic arrest, and apoptosis. [EMBO J] Full Article

CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy
Scientists developed functional evidence for CBP and PTEN interaction in prostate cancer based on findings of their correlate expression in the human disease. Cbppc-/-; Ptenpc+/- mice exhibited higher cell proliferation in the prostate and an early onset of high-grade prostatic intraepithelial neoplasia. [Cancer Res] Abstract

Fatostatin Displays High Anti-Tumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling
Researchers evaluated the anti-prostate tumor activity of a novel sterol regulatory element-binding proteins (SREBP) inhibitor, fatostatin. They found that fatostatin suppressed cell proliferation and anchorage-independent colony formation in both androgen-responsive LNCaP and androgen-insensitive C4-2B prostate cancer cells. [Mol Cancer Ther] Abstract

Genistein Downregulates Onco-miR-1260b and Upregulates sFRP1 and Smad4 via Demethylation and Histone Modification in Prostate Cancer Cells
Researchers focused on the gene regulatory effect of genistein on microRNA (miR) and its target genes in prostate cancer (PC). Genistein promoted apoptosis while inhibiting prostate cancer cell proliferation, invasion and TCF reporter activity in PC cells. [Br J Cancer] Abstract

Novel Pharmacologic Targeting of Tight Junctions and Focal Adhesions in Prostate Cancer Cells
Genome-wide analysis in the human prostate cancer cell line DU-145 identified primary downregulated targets of DZ-50, including genes involved in focal adhesion integrity, tight junction formation as well as insulin growth factor binding protein 3 and the angiogenesis modulator thrombospondin 1. [PLoS One] Full Article

The Reciprocal Interactions between Astrocytes and Prostate Cancer Cells Represent an Early Event Associated with Brain Metastasis
Researchers investigated whether the interactions between prostate cancer cells and cortical astrocytes are associated to a potential role for astrocytes in tumor establishment. They demonstrated that astrocytes interact in vitro with prostatic cancers cells derived from different metastatic sites. [Clin Exp Metastasis] Abstract

Metformin Anti-Tumor Effect via Disruption of the MID1 Translational Regulator Complex and AR Downregulation in Prostate Cancer Cells
Metformin showed an anti-proliferative effect on a wide range of prostate cancer cells. It disrupted the AR translational MID1 regulator complex leading to release of the associated AR mRNA and subsequently to downregulation of AR protein in AR positive cell lines. [BMC Cancer] Abstract | Full Article

Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants
Researchers demonstrated that SPOP recognizes a Ser/Thr-rich degron in the hinge domain of androgen receptor (AR) and induces degradation of full-length AR and inhibition of AR-mediated gene transcription and prostate cancer cell growth. [Cell Rep] Abstract | Graphical Abstract


Randomized Phase II Trial of Nintedanib, Afatinib and Sequential Combination in Castration-Resistant Prostate Cancer
Investigators evaluated afatinib, an ErbB family blocker, and nintedanib, a triple angiokinase inhibitor, in castration-resistant prostate cancer patients. [Future Oncol] Abstract

Genetic Variants in the CYP24A1 Gene Are Associated with Prostate Cancer Risk and Aggressiveness in a Korean Study Population
Scientists identified the relationships between polymorphisms in CYP24A1 and prostate cancer in a Korean cohort. They evaluated the association between 21 single-nucleotide polymorphisms in the CYP24A1 and prostate cancer in Korean men. [Prostate Cancer Prostatic Dis] Abstract

Win a $25 Amazon Gift Card!
Connexon Creative is evaluating reader interest in a new social media platform. Fill out this quick survey for your chance to win 1 of 4 $25 gift cards! Take survey here

Derivation of Metabolically Active Hepatocytes from Pluripotent Stem Cells - View On-Demand Webinar Now.
Targeting Metastatic Castration-Resistant Prostate Cancer: Mechanisms of Progression and Novel Early Therapeutic Approaches
The authors summarize the current literature on the biology of metastatic castration-resistant prostate cancer. The emerging data are increasing understanding of the mechanisms that underlie the pathogenesis of castrate resistance and where future treatment might be headed. [Expert Opin Investig Drugs] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Ipsen Announces Positive Top Line Results from Phase III Clinical Study of Decapeptyl® (Triptorelin Pamoate) 11.25 mg Administered Subcutaneously in Patients with Prostate Cancer
Ipsen announced that the Phase III clinical trial evaluating Decapeptyl® (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints. [Ipsen] Press Release

Stem Cell Agency Funds More Than $66 Million in Research Including New Genomics Initiative
A team bringing together experts and investigators from seven different major California institutions has been awarded $40 million to create a new Center of Excellence in Stem Cell Genomics, by California’s stem cell agency, the California Institute for Regenerative Medicine. [California Institute for Regenerative Medicine]
Press Release

Data on More Than 10,000 Cancer Genomes Released by the International Cancer Genome Consortium
The International Cancer Genome Consortium announced that it has made available to the scientific community data from more than 10,000 cancer genomes. The data can be used by cancer researchers around the world to better understand the genomic basis of cancer, accelerate cancer research and aid in the development of more targeted treatments. [International Cancer Genome Consortium] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
Judges Side with FDA on Stem Cells
The D.C. Circuit Court of Appeals ruled that culturing a patient’s stem cells for therapeutic use falls under the aegis of the US Food and Drug Administration (FDA). FDA has said therapeutic stem cells should be regulated as drugs. [The Scientist] Editorial | Court Ruling

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 12th CIMT Annual Meeting “Next Waves in Cancer Immunotherapy”
May 6-8, 2014
Mainz, Germany

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Position- Cancer Biology/Genomics (Weill Cornell Medical College)

NEW Experienced Researcher – Detection of Prostate Cancer Biomarkers (Dublin City University)

Postdoctoral Fellow – Role of Mitochondria in Cancer Progression (Baylor College of Medicine)

Postdoctoral Position – Prostate Cancer (Roswell Park Cancer Institute)

Postdoctoral Position – Prostate Molecular Oncology (Trinity College Dublin)

Postdoctoral Fellow – Molecular Mechanisms of Cancer Progression (University of South Alabama)

Postgraduate Position – Chemokine Receptor Induced Cell Migration (University of East Anglia)

Graduate Student Position – Epigenetics and Chromatin (University of Victoria)

Postdoctoral Fellow – Mechanism of Prostate Cancer Bone Metastasis (Georgia Regents University)

Postdoctoral Position – Stem Cells and Bioengineering (Queensland University of Technology/Translational Research Institute)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Prostate Cell News: Archives | Events | Contact Us